Current status and hurdles for CAR-T cell immune therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is a developing immunotherapy for hematological malignancies.
• CAR-T therapy involves genetically modifying a patient's T cells to target cancer cells.

Purpose of the Study:

• To review the critical components, challenges, and future directions in CAR-T cell therapy development and application.
• To highlight advancements and limitations in CAR-T cell therapy for various cancers.

Main Methods:

• Review of current literature on CAR-T cell vector design, gene delivery systems, and preclinical models.
• Analysis of clinical outcomes, challenges (relapse, adverse effects), and strategies for solid tumors.

Main Results:

• CAR-T therapy has achieved complete remission in acute lymphoblastic leukemia, lymphoma, and multiple myeloma.
• Challenges include lack of specific targets for acute myeloid leukemia, leukemia relapse, cytokine release syndrome, neurotoxicity, and limitations in treating solid tumors.

Conclusions:

• Optimizing CAR-T cell design, delivery, and preclinical models is crucial.
• Addressing current hurdles is essential for expanding CAR-T cell therapy's clinical application and efficacy.